Itamar Medical. Investor Presentation August 2018
|
|
- Chloe Holmes
- 5 years ago
- Views:
Transcription
1 Itamar Medical Investor Presentation August 2018
2 Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection with the investment outlined herein. Prospective investors are urged to conduct an independent evaluation of the Company. This presentation does not constitute an offer of securities of the Company, or a solicitation to acquire or sell the Company s securities or to participate in any investment in the Company. The statements in this presentation should not be regarded as a basis for an investment decision of any kind, or as recommendation or opinion, or a substitute for investor discretion Statements in this presentation that are not historical facts might be considered as forward-looking statements based on current expectations of future events, in accordance with the Israeli Securities law, (the Securities Law ). These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements as a result of different factors including, but not limited to, the market demands for the Company's products; changes in general economic and business conditions; inability to maintain market acceptance of the Company's products; inability to timely develop and introduce new technologies and products; rapid changes in the market for the Company's products; loss of market share and pressure on prices resulting from competition; introduction of competing products by other companies; inability to manage growth and expansion; inability to attract and retain qualified personnel; changes in regulatory requirement, changes in scope of reimbursement, and inability to protect the Company's proprietary technology. All forward-looking statements included in this presentation are made only as of the date of this presentation. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events, regulatory changes, delay or withholding of regulatory approvals, inability to obtain or maintain medical insurance reimbursement for Company's products, negative results of clinical trials or other factors. The United States and Israeli securities laws prohibit any person who has material non-public information about a company ("Inside Information"), from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. Statements in this presentation and in any information given during this presentation might be considered as Inside Information, in accordance with the Securities Law. Therefore, any person aware of this presentation or of any information given during this presentation, may neither use, nor cause any third party to use, any Inside Information or any other information provided in connection with the presentation, in contravention of the Securities Law or any such rules and regulations thereunder. The Company, and its respective affiliates, employees and representatives expressly disclaim any and all liability relating to or resulting from the use of this presentation or any information given during this presentation or such other information by a prospective investor or any of its affiliates or representatives.
3 Itamar Medical Mission World Leader in Sleep Apnea Management Solutions for the Cardiology Market
4 Leader in Diagnostics of Sleep Apnea to the Cardio Space Flagship product: WatchPAT is a fast growing home sleep apnea test ( HSAT ) Sleep Apnea market growing at record rates propelled by cardiology, obesity and stress Powerful partnerships: Medtronic: co-marketing agreement and shareholder Philips: Bilateral distribution agreement (US/Japan) Increasing traction among cardiologists supported by new guidelines and direct US sales force Consistent quarter over quarter revenue growth Multiple regulatory approvals (FDA, CE, MHLW), broad insurance coverage Experienced management team and board members with proven success
5 The Market The Sleep Market The Cardiology Market Source: 25% of adults worldwide suffer from sleep apnea 1 About 80% in the US alone are undiagnosed 2 The diagnostic and treatment market is valued at $ 3.5 billion 3 1- American Academy of Sleep Medicine, Peppard, et al., American Journal of Epidemiology (2013) 2- Obstructive Sleep Apnea: Preoperative Assessment, Seet & Chung, Anesthesiology Clin 28 (2010) Fisher & Paykel, FY2016 Half Year results Presentation (Dx & Tx) 4- Heart Disease and Stroke Statistics 2017 At-a-Glance 5- Sleep Apnea and Cardiovascular Disease, JACC Vol. 52, No. 8, 2008, August 19, 2008: million cardiovascular patients in the United States 4 ~50% of patients suffer from sleep apnea; most of them (80% or more) are not diagnosed 5
6 Sleep Apnea - a Significant Comorbidity to Most Cardiac Disease OSA Comorbidity Drug resistant hypertension Congestive heart failure Type 2 Diabetes 76% 72% 83% Stroke Pacemakers Arrhythmias Coronary heart disease Atrial fibrillation 63% 59% 58% 57% 49% Source: Obstructive Sleep Apnea: Preoperative Assessment, Seet & Chung, Anesthesiology Clin 28 (2010)
7 Trends propelling the market Source: Sleep Apnea Types, Mechanisms, and Clinical Cardiovascular Consequences, Javaheri,et al, JACC VOL. 69, NO. 7,
8 Increased Risks of Leaving Sleep Apnea Untreated 2x 2x Increased risk of stroke 1 Risk of death from sudden cardiac arrest 2 5x Risk of death from cardiovascular disease 3 42% Increased risk of recurrence of atrial fibrillation following ablation 4 Sources: 1) Sleep Apnea and Incident Stroke, Redline et al, The Sleep Heart Health Study. American Journal of Reppiratory and Critical Care Medicine Vol ; 2) Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death Gami et al, J Am Coll Cardiol 2013: 3) Young et al, J Sleep 2008; 4) Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence Shukla, Chinitz JACC Clinical Electrophysiology Vol 1,No 1-2, 2015
9 The American Academy of Sleep Medicine Officially Adopts Itamar Medical s technology for the Diagnosis of Sleep Apnea The leading U.S. medical organization for the treatment of sleep disorders began officially recognizing the PAT technology in its guidelines for clinical practice in 2017 Source: J Clin Sleep Med Mar 15; 13(3):
10 Strategy Implementation - a Unique Comprehensive Solution that enables Diagnosis and Treatment Total Sleep Solution Screening Diagnosing Treatment Reporting Itamar provides cardiologists with a comprehensive sleep solution, combining diagnostics and therapy
11 WatchPAT: More Effective/Easier to Use A medical grade, prescription device designed for easy at-home use The traditional way: Cumbersome sleep labs
12 WatchPAT: Integrated Platform To Diagnose and Treat Sleep Apnea A One-Stop Sleep Apnea Solution for Cardiologists Screening Diagnosing Treatment Reporting Systematic Screening with Questionnaire Patient awareness kits Waiting room video Waiting room posters Informative brochure Diagnosis with WatchPAT IDTF WatchPAT Direct Interpretation through CouldPAT collaboration with Sleep Physician CPAP treatment Philips CPAP distribution Airway Mng MAD DMEs Networks Patient Compliance Reporting Waiting list WatchPAT Test result CPAP Patient CPAP compliance rate Sleep Apnea prevalence rate SleepPath
13 Sleep Monitoring Platform - SleePath Integrated Sleep Apnea Patient Care Pathway for AFib Patients E-health could based platform
14 Multiple Business Models for Different Needs Therapeutic SleePath, CPAP and PAMS Services WatchPAT Direct Total Sleep Solutions Capital Sales WatchPAT TaaS Test as a Service
15 WatchPAT Direct Program Streamlining the HST A customizable workflow to enlarge the HST coverage Schedule the study with the patient Kit preparation Shipping & Handling Patient Support Center 24/7 Home Sleep Test Scoring & Reporting
16 Maximizing Value at a Fast Growing Market Making Total Sleep Solution" available to cardiologists Adding additional business model of Test as a Service ( TaaS ) Cardiology centered marketing and sales Adoption of PAT based technology by the Organization of Sleep Specialists
17 Consistent Sales growth
18 Consistent Revenue Growth Quarterly Revenue ($MM) $7.0M $6.0M $5.0M $4.0M $4.3M $3.6M $5.1M $4.0M $5.3M $4.2M $6.0M +26%* $5.5M +21%* $3.4M +20%* $6.1M +23%* $4.5M $3.0M $2.9M $2.0M $1.0M - Q1/17 Q2.17 Q3/17 Q4/17 Q1/18 Q2/18 * Q over PY Q US and Canada Revenue Total Revenue
19 Consistent Operational Loss Reduction Cash Based Operating Loss Non GAAP $2.5M $2.2M $2.0M $1.7M $1.5M $1.5M $1.5M $1.4M $1.0M $1.0M $0.7M $0.5M $0.5M $0.5M $0.4M - Q1/16 Q2/16 Q3/16 Q4/16 Q1/17 Q2/17 Q3/17 Q4/17 Q1/18 Q2/18
20 Experienced Management Team Gilad Glick President and CEO Shy Basson CFO Dr. Koby Sheffy Senior Vice President and CTO Ira Prigat President of Itamar Medical Japan & China Efrat Litman V.P. of R&D Itay Kariv V.P. Advanced R&D Shlomo Ayanot V.P. Engineering and Operations
21 Thank You!
22 PARAMETERS Simplicity of Pulse Oximetry the Accuracy of PSG 8+ parameters + sleep stages, + true sleep time Lab PSG Home PSG WatchPAT Completion rate 99% vs 82% Misdiagnosis 3% vs 20% 4-5 parameters AHI, RDI, snoring, position Cardio Pulmonary Systems 1-2 parameters saturation motion Pulse Oximetry SIMPLICITY / COMFORT
23 Comp - irhythm irhythm Technologies, Inc. (IRTC) Nasdaq
Itamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationITAMAR MEDICAL LTD. (Name of registrant)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month
More informationItamar Medical. Investors Presentation. June 2016
Itamar Medical Investors Presentation June 2016 Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationItamar Medical. November 2016
Itamar Medical November 2016 Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible
More informationTotal Sleep Solution. Growing Cardiac Sleep Health Management. Together. Health Being Made Simple
Total Sleep Solution Growing Cardiac Sleep Health Management. Together. Health Being Made Simple Total Sleep Solution Sleep Apnea Management Improves Cardiac Health and Therapy Efficacy Sleep Apnea is
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationIntroducing the WatchPAT 200 # 1 Home Sleep Study Device
Introducing the WatchPAT 200 # 1 Home Sleep Study Device Top 10 Medical Innovation for 2010 Cleveland Clinic Fidelis Diagnostics & Itamar Medical Fidelis Diagnostics founded in 2004, is a privately-held
More informationBarriers to Integrating Sleep Medicine into Cardiology Care New Insights Into Afib Ablation: Can Sleep Apnea Fill in the Gap? Featured Articles:
Volume 1 Number 1 May 2018 Featured Articles: Barriers to Integrating Sleep Medicine into Cardiology Care New Insights Into Afib Ablation: Can Sleep Apnea Fill in the Gap? Dedicated to the nexus of Cardiology
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationOventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane
Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane February 2018 Twitter: @OventusLtd About Oventus (ASX: OVN) Oventus is commercialising its Airway Technology
More informationWorld leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
More informationAbout VirtuOx. Was marketed exclusively by Phillips Healthcare division, Respironics for 3 years
About VirtuOx VirtuOx, Inc. assists physicians and Durable Medical Equipment (DME)( companies diagnose respiratory diseases and qualify patients for home respiratory equipment under the guidelines of CMS
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationCOMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #277: Sleep Apnea: Severity Assessment at Initial Diagnosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION
More informationThis document contains certain forward-looking statements, relating to Rhinomed Limited s (Rhinomed) business which can be identified by the use of
BIOSHARES JULY 2016 This document contains certain forward-looking statements, relating to Rhinomed Limited s (Rhinomed) business which can be identified by the use of forward looking terminology such
More informationFor personal use only
ASX Release Oventus presentation for AGM of Thorney Technologies Ltd Brisbane, Australia 24 th November 2017: Oventus Medical Ltd (ASX: OVN) is pleased to release a copy of the presentation that Founder
More informationRespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,
More informationASK US. A Study for Obstructive Sleep Apnea Patients Using a New At-Home Sleep Test ARE YOU ABOUT THE STUDY #
#15420040.0 A Study for Obstructive Sleep Apnea Patients Using a New At-Home Sleep Test STUDY DENTIST Dr. Michael Simmons DMD, MSc ARE YOU Struggling with or given up on CPAP and don t know what to do?
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationPOLICY All patients will be assessed for risk factors associated with OSA prior to any surgical procedures.
Revised Date: Page: 1 of 7 SCOPE All Pre-Admission Testing (PAT) and Same Day Surgery (SDS) nurses at HRMC. PURPOSE The purpose of this policy is to provide guidelines for identifying surgical patients
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationFA et Apnée du Sommeil
FA et Apnée du Sommeil La Réunion Octobre 2017 Pascal Defaye CHU Grenoble-Alpes Obstructive Sleep Apnea and AF Incidence of atrial fibrillation (AF), based on presence or absence of OSA. Cumulative frequency
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationQuality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care
Quality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationPROFOUND MEDICAL CORP.
PROFOUND MEDICAL CORP. Pioneering a new standard of care in the treatment of prostate cancer Forward-Looking Statements This presentation and oral statements made during this meeting regarding Profound
More informationFor personal use only. Better Sleep, Better Health and a Better Life
Better Sleep, Better Health and a Better Life Investor Update December 2016 Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationCorporate Presentation. June 2017
v Corporate Presentation June 2017 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationUIHC Home Sleep Apnea Testing (HSAT)
UIHC Home Sleep Apnea Testing (HSAT) Lisa Mertens, ARNP, RRT Department of Neurology, Sleep Division Iowa River Landing East (IRL East) Respiratory Care Seminar October 19, 2018 1 Home Sleep Apnea Test
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationSleep apnea devices Market Research Report- Global Forecast To 2022
Report Information More information from: https://www.marketresearchfuture.com/reports/2061 Sleep apnea devices Market Research Report- Global Forecast To 2022 Report / Search Code: MRFR/HC/1529-HCRR Publish
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationInvestor Presentation. Q May 21, 2018
Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationAsia-Pacific Electrophysiology Market Outlook to 2020
Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationPremier Health Plan considers Oral Appliances for Obstructive Sleep Apnea (OSA) medically necessary for the following indications:
Premier Health Plan POLICY AND PROCEDURE MANUAL MP.063.PH - al Appliances for Obstructive Sleep Apnea This policy applies to the following lines of business: Premier Commercial Premier Employee Premier
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationFor personal use only CHANGING THE WAY THE WORLD BREATHES
CHANGING THE WAY THE WORLD BREATHES - MAY 2016 NASAL RESPIRATORY TECHNOLOGY COMMERICAL IN CONFIDENCE WWW..GLOBAL WWW..GLOBAL Disclaimer This document contains certain forward-looking statements, relating
More informationFAQ CODING & REIMBURSEMENT. WatchPAT TM Home Sleep Test
FAQ CODING & REIMBURSEMENT WatchPAT TM Home Sleep Test TABLE OF CONTENTS PATIENT SELECTION CRITERIA 3 CODING & MODIFIERS 4-6 PLACE OF SERVICE 6 FREQUENCY 7 ACCREDITATION 7 SLEEP MEDICINE GLOSSARY AND ACRONYMS
More informationMedicare CPAP/BIPAP Coverage Criteria
Medicare CPAP/BIPAP Coverage Criteria For any item to be covered by Medicare, it must 1) be eligible for a defined Medicare benefit category, 2) be reasonable and necessary for the diagnosis or treatment
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationCERT PAP Errors: The DME CERT Outreach and Education Task Force Responds
CERT PAP Errors: The DME CERT Outreach and Education Task Force Responds DME CERT Outreach and Education Task Force National PAP Webinar, December 17, 2014 PAP CERT Errors Medical Records: Face-to-Face
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationGOALS. Obstructive Sleep Apnea and Cardiovascular Disease (OVERVIEW) FINANCIAL DISCLOSURE 2/1/2017
Obstructive Sleep Apnea and Cardiovascular Disease (OVERVIEW) 19th Annual Topics in Cardiovascular Care Steven Khov, DO, FAAP Pulmonary Associates of Lancaster, Ltd February 3, 2017 skhov2@lghealth.org
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationRULES OF CONDUCT OF INSIDERS RESPECTING
T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationObstructive Sleep Apnea
Obstructive Sleep Apnea Definition: Repetitive episodes of upper airway obstruction (complete or partial) that occur during sleep and are associated with arousals or desaturations +/or daytime sleepiness.
More informationNORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director
Robert Ullman Managing Director rullman@dinancapital.com 45.63.44 NORTH AMERICAN DERMATOLOGY M&A Activity and Valuation Trends Q4 205 William Downing Director wdowning@dinancapital.com 602.734.0682 Michael
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationCorporate Presentation. First Quarter 2018
Corporate Presentation First Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationMission Statement for our Arrhythmia Care
Mission Statement for our Arrhythmia Care We are dedicated to provide a compassionate and an outstanding care for patients with cardiac arrhythmias. We will be utilizing the cutting edge and the most advanced
More information